Market Trend'Heat Vaccination' As A Biopharmaceutical Opportunity
With climate change accelerating, a little-explored frontier in medicine could offer new ways to protect people from heat stress while creating a potentially transformative market opportunity.Dieu Anh Nguyen•
PharmaceuticalThe Reality Behind AstraZeneca’s £300m UK “Win”
While politically framed as a major UK success for biotech, AstraZeneca’s £300 million investment more likely reflects improved commercial conditions than a global shift in biotech leadership.Miriam Saif•
Industry TrendsThe Life Sciences Industry in the New Era of Cybersecurity
As geopolitical tensions rise and AI supercharges cyber threats, Life Sciences companies must treat cybersecurity as mission-critical-not just to protect valuable research, but to safeguard operations and patient lives.Dieu Anh Nguyen•
PharmaceuticalCould a Daily Pill Replace Ozempic? The Race to Make Weight-Loss Drugs Easier to Take
The arrival of oral GLP-1 pills signals a major turning point in obesity treatment — shifting the market beyond injections.Kyra Sharma•
PharmaceuticalNovo Nordisk’s Integration of OpenAI
eleanor g•
Industry TrendsMeningitis B Vaccine Shortage: Why it Happens
Kyra Sharma•
Industry TrendsGovernment Goodwill as a Competitive Edge: Strategic Takeaways from South Korea’s Pharma Partnerships
Dieu Anh Nguyen•
Industry TrendsHow the Iran Conflict Could Disrupt Global Pharmaceutical Supply Chains
Kyra•
Market TrendThe Legal Logic Behind Big Pharma's MASH Buying Spree
Dieu Anh Nguyen•- M&A
The Push Toward Oral Obesity and Diabetes Biologics
Miriam Saif• 
M&AEli Lilly Strengthens In Vivo Platform with Orna Therapeutics Acquisition
Eleanor G•
Clinical TrialsWhy Phase II Trials Break More Biotech Companies Than Bad Science
Kyra•
Market TrendPharma's Big Bet on Sports Advertising: Lessons from the Super Bowl and Olympics
Dieu Anh Nguyen•- Market Trend
Alzheimer's Therapeutics: Renewed Investment and Emerging Opportunities
Miriam Saif• 
PharmaceuticalSkinny labels – the cause of disputes between drug makers
Dieu Anh Nguyen•
Market TrendOperational Decisions Becoming Strategic Signals in Biotech
Miriam Saif•
Market TrendAstraZeneca’s Asia Gamble
eleanor g•
Case StudyUS–UK Pharma Deal Reprices the UK Market
Sisir Kalavala•
Case StudyHow a Biological Database Company Sells Electronic Shovels in the AI Gold Rush
Dieu Anh Nguyen•
PharmaceuticalNew EU Drug Rules: A Game-Changer for Start-Ups
Miriam Saif•
PharmaceuticalNovo Nordisk’s Path Through Recent Challenges
Eleanor G•
Case StudyFlagship Pioneering: Reinventing Venture Capital in Biopharma
Dieu Anh Nguyen•- Market Trend
Fruit Flies in Drug Discovery: Faster, Cheaper, Smarter Early Screening
Miriam Saif• 
Case StudyHow Eli Lilly reached a $1 Trillion Valuation
eleanor g•
M&AJohnson & Johnson's Acquisition of Halda Therapeutics: Expanding Precision Oncology Capability
Sisir Kalavala•
M&APfizer-Novo-Metsera dispute: lessons to learn on biotech-pharma M&A deals
Dieu Anh Nguyen•- BioTech
How AI and Automation are Opening the Door to Biotech Innovators
Miriam Saif• 
Case StudyBrexit and the UK Biopharma Industry
Eleanor G•
Spin-OffsKimberly-Clark's $32 Billion Acquisition of Kenvue: A Strategic Realignment in Global Healthcare
Sisir Kalavala•
Market TrendWhy Pharma Companies are Investing in U.S. Direct-to-Consumer Sales: Insights on Pharmaceutical Distribution
Dieu Anh Nguyen•- BioTech
Gut Instincts: How Microbiome Science Can Reshape Addiction Medicine
Miriam Saif• 
Case StudyHaleon’s Success Three Years After Leaving GSK
Eleanor G•
Spin-OffsJohnson & Johnson's DePuy Synthes Spin-Off
Sisir Kalavala•
Case StudyThree FDA Rejections Later: The Lessons Behind Xspray Pharma’s Dasynoc™ Setback
Dieu Anh Nguyen•
PharmaceuticalGSK Enters a New Era Under Incoming CEO Luke Miels
Sisir Kalavala•
BioTechWhat to Take Away From Takeda's Discontinuation of Cell therapy?
Dieu Anh Nguyen•
